Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.5600 (3.35%) ($9.3300 - $9.5600) on Tue. Feb. 15, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.22% (three month average) | RSI | 55 | Latest Price | $9.5600(3.35%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.1% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(64%) IWO(53%) IWM(49%) IWC(48%) XBI(48%) | Factors Impacting FOLD price | FOLD will decline at least -2.11% in a week (0% probabilities). VIXM(-29%) VXX(-13%) UUP(-12%) UNG(-9%) EDOC(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.11% (StdDev 4.22%) | Hourly BBV | 1.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $9.31(2.69%) | 10 Day Moving Average | $9.19(4.03%) | 20 Day Moving Average | $9.22(3.69%) | To recent high | -23.2% | To recent low | 10.3% | Market Cap | $2.469b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |